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Abstract
Background -: Beta-2 adrenergic receptor gene polymorphisms Gln27Glu, Arg16Gly and
Thr164Ile were suggested to have an effect in heart failure. We evaluated these polymorphisms
relative to clinical characteristics and prognosis of alarge cohort of patients with heart failure of
different etiologies.
Methods -: We studied 501 patients with heart failure of different etiologies. Mean age was 58
years (standard deviation 14.4 years), 298 (60%) were men. Polymorphisms were identified by
polymerase chain reaction-restriction fragment length polymorphism.
Results -: During the mean follow-up of 12.6 months (standard deviation 10.3 months), 188 (38%)
patients died. Distribution of genotypes of polymorphism Arg16Gly was different relative to body
mass index (χ2 = 9.797;p = 0.04). Overall the probability of survival was not significantly predicted
by genotypes of Gln27Glu, Arg16Gly, or Thr164Ile. Allele and haplotype analysis also did not
disclose any significant difference regarding mortality. Exploratory analysis through classification
trees pointed towards a potential association between the Gln27Glu polymorphism and mortality
in older individuals.
Conclusion -: In this study sample, we were not able to demonstrate an overall influence of
polymorphisms Gln27Glu and Arg16Gly of beta-2 receptor gene on prognosis. Nevertheless,
Gln27Glu polymorphism may have a potential predictive value in older individuals.
Background
Genetic polymorphisms have been studied with the
hypotheses of influencing presentation, course and prog-
nosis of patients with heart failure [1]. Beta-2 adrenergic
receptor gene polymorphisms Gln27Glu, Arg16Gly, and
Thr164Ile were suggested to have a significant effect in
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patients with heart failure. In a study of 259 patients with
ischemic or idiopathic dilated cardiomyopathy, prognosis
was less favorable in patients harboring the allele Ile164
relative to patients harboring the allele Thr164. In patients
harboring alleles Gly16 and Glu27, previoulsy associated
with increased down regulation of beta-2 adrenergic
receptors, a statistically significant difference relative to
prognosis has not been demonstrated. However, a trend
to a prognostic influence of allele Gly16 was suggested by
an apparent and non-significant lower survival rate in
patients harboring allele Gly16 [2]. The polymorphisms
Thr164Ile, Arg16Gly and the haplotypes with alleles
Gly16 and Gln27 were associated with reduced exercise
tolerance in other study that enrolled 232 patients with
idiopathic dilated cardiomyopathy or ischemic cardiomy-
opathy [3]. These findings substantiate the hypotheses
that polymorphisms Arg16Gly, Gln27Glu and Thr164Ile
of beta-2 receptor gene might be functional and might be
associated with differences in the survival rate of patients
with heart failure. Therefore, due to sparse and sometimes
conflicting results, this hypothesis deserves further testing
in different populations.
We performed this study to evaluate the polymorphisms
Gln27Glu, Arg16Gly, and Thr164Ile of the beta-2 receptor
gene relative to demographic and clinical variables, as
well as, survival rate in a series of patients with heart fail-
ure of different etiologies.
Methods
Study population
501 patients with heart failure in functional class III or IV
of the New York Heart Association were studied. Patients
aged 58 (SD 14.4) (minimum 18; maximum 93; median
59) years, 298 (60%) were men and 203 women. The
patients were included in the study from August, 2002 to
March, 2004.
The diagnosis of heart failure was made according to pre-
viously published criteria [4]. The classification of the eti-
ologies of heart failure followed previous
recommendations [5-7]. As such, the diagnosis of chronic
heart failure was made through both clinical and imaging
procedures when necessary. Ischemic cardiomyopathy
diagnosis this was made when a clear history of previous
myocardial infarction and no other probable cause of
heart dysfunction was present or, alternatively, through
coronary angiography. All patients with the final diagno-
sis of idiopathic dilated cardiomyopathy were studied
through coronary angiography to exclude the diagnosis of
ischemic cardiomyopathy.
Clinical characteristics of the patients
367 (73%) patients were white, 121 (24%) were mullat-
toes, and 13 (3%) were from other ethnicities.
Hypertensive cardiomyopathy was diagnosed in 144
(29%) patients, ischemic cardiomyopathy in 143 (29%),
cardiomyopathy due to valve disease in 76 (15%), Cha-
gas'heart disease in 60 (12%). Other etiologies were diag-
nosed in 28 (6%) patients. Heart failure was ascribed to
idiopathic dilated cardiomyopathy in 50 (10%) patients.
One-hundred and twenty nine (26%) patients were dia-
betic (type II).
The distribution of body mass index (evaluated in 362
patients) was: < 18.5 kg/m2 in 26 (7%) patients, 18.5-25
kg/m2 in 160 (44%), 25-30 kg/m2 in 112 (31%) and > 30
kg/m2 in 64 (18%).
Sinus cardiac rhythm was diagnosed in 304 (61%)
patients, atrial flutter or fibrillation in 123 (25%) and was
not retrieved in 74 (15%).
Drug regimens used in therapy at enrollment (baseline of
follow-up) included diuretics (mainly furosemide) in 356
(71%) patients, angiotensin converting enzyme inhibitors
in 330 (66%), digoxin in 264 (52%), antiplatelet agents
113 (22%), beta-blockers (mainly carvedilol) in 102
(20%), warfarin in 96 (19%), spironolactone in 77
(15%), nitrates in 75 (15%), other vasodilators in 49
(10%), amiodarone in 40 (8%). After enrollment and
during follow-up angiotensin converting enzyme inhibi-
tors, angiotensin II receptor blockers, beta-blockers and
spironolactone were titrated until maximum dose or dose
tolerated by patients was achieved.
Other clinical and laboratory characteristics of the
patients in this study sample are shown in Table 1.
Genotype determination
Genomic DNA was extracted from leukocytes in samples
from whole blood, following standard techniques. The
three studied polymorphisms were detected by polymer-
ase chain reaction-restriction fragment length polymor-
phism, as previously described [8].
Quality control for these assays was assessed by randomly
selecting 50 samples to be re-genotyped by two independ-
ent technicians.
Studied variables
Polymorphisms Gln27Glu, Arg16Gly, and Thr164Ile of
beta-2 adrenergic receptor gene were studied relative to
sex, ethnicity, age, duration of symptoms, etiology of
heart failure, diabetes mellitus, history of arterial hyper-
tension, smoking, body mass index (kg/m2), heart rate,
blood pressure, cardiac rhythm, cardiac dimensions on
echocardiography, left ventricle ejection fraction, serum
sodium, hemoglobin, serum cholesterol and triglycerides,BMC Cardiovascular Disorders 2009, 9:50 http://www.biomedcentral.com/1471-2261/9/50
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HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol,
serum glucose, creatinine, drug therapy, and outcome.
Follow-up
The follow-up was assessed in the last outpatient medical
visit or by telephone contact. In addition, the mortality
database of São Paulo City Authority was also scrutinized
to discover patient deaths (ProAim--Programa de Aprimo-
ramento de Informações de Mortalidade do Municipio de
São Paulo). Last follow-up was evaluated in April, 2006.
Main end-point studied was overall mortality.
Statistical analysis
After descriptive statistics to evaluate the sample profile,
the distribution of polymorphisms was tested for Hardy
Weinberg equilibrium. The distribution of genotypes was
compared to population samples reported in previous
studies [9]. Comparison of proportions was used to test
the distribution of the studied genotypes relative to other
demographic and clinical variables. Haplotype determi-
nation was conducted using the Haploview software (ver-
sion 4.1).
The probability of survival was evaluated by the Kaplan
Meier method relative to demographic and clinical varia-
bles and relative to genotypes and alleles of studied poly-
morphism. Comparisons were made with the log-rank
test. Death (overall) was considered an event.
A Cox proportional hazard regression model was adjusted
for assessing the independent variables associated with
prognosis; variables were selected through stepwise as
well as a manual procedure (in the order they appear in
Table 2).
Classification trees were used for exploratory analysis of
potential interactions in regarding to mortality. Used
growing method was CHAID. Significance level for split-
ting nodes was 0,05 and for merging categories was 0,05.
Model estimation was performed with the maximum
number of iterations of 100, and Bonferroni method was
used to adjust for multiple comparisons.
Statistical analyses were performed with R software [9] or
SPSS statistical package 13.0. A p value < 0.05 was consid-
ered significant.
Table 1: Clinical and laboratory characteristics of the study 
sample
Variable n Mean Standard deviation
Age (years) 501 58 14.4
Body weight (kg) 414 67.6 15.7
Height (m) 371 1.63 0.09
Body mass index (kg/m2) 362 25.6 5.6
Heart rate, bpm 431 79.6 13
Blood pressure (mm Hg)
Diastolic 450 76 18.4
Systolic 450 121.9 30.9
Echocardiography
Interventricular septum (cm) 435 0.97 0.23
Left ventricle
Posterior wall (cm) 435 0.95 0.2
Diastolic diameter (cm) 444 6.2 1.15
Systolic diameter (cm) 338 4.97 1.42
Ejection fraction (%) 397 45 19
Interventricular septum (cm) 435 0.97 0.23
Aorta (cm) 425 3.26 0.59
Left atrium (cm) 438 4.68 0.9
Right ventricle (cm) 192 2.73 0.87
Serum sodium (mEq/L) 481 136.7 4.5
Hemoglobin (g/dL) 479 13.07 2.1
Serum cholesterol (mg/dL) 400 190.1 51.6
Triglycerides (mg/dL) 398 123.1 66.7
HDL-cholesterol (mg/dL) 393 45.1 15.4
LDL-cholesterol (mg/dL) 394 120.1 42
VLDL-cholesterol (mg/dL) 389 24.8 13.6
Serum creatinine (mg/dL) 487 1.3 0.74
Table 2: Mortality relative to studied variables including information derived from exploratory analysis (Cox proportional hazards 
model)
Variables p Hazard ratio 95% Confidence interval
Serum sodium < 0.001 0.94 (0.91; 0.96)
Serum creatinine < 0.001 1.47 (1.27; 1.69)
Etiology 0.09 0.91 (0.81; 1.02)
Ethnicity 0.73 0.97 (0.80; 1.17)
Gln27Glu # 0.01 5.48 (1.50; 20.08)
Age < 0.001 1.03 (1.02; 1.05)
Age * Gln27Glu # 0.004 0.97 (0.95; 0.99)
Baseline beta-blocker use 0.001 2.30 (1.43; 3.71)
# dominant model (GlnGln genotype reference versus GlnGlu + GluGlu genotypes)
Serum sodium, serum creatinine and age included as continuous variables
Etiology (1. Chagasic, 2 Idiopathic, 3 Hypertensive, 4 Isquemic, 5 Heart failure due to valve disease)BMC Cardiovascular Disorders 2009, 9:50 http://www.biomedcentral.com/1471-2261/9/50
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Ethics
The study protocol was approved by the Ethics Committee
for Medical Research of the Hospital das Clinicas Univer-
sidade de São Paulo. Informed consent was obtained and
signed by all participants.
Results
Distribution of alleles and genotypes
The distribution of allele frequencies, genotypes, and hap-
lotypes are shown in Table 3. For polymorphism
Thr164Ile, 97% of the samples were homozygous for the
Thr164Thr genotype and 3% heterozygous for Thr164Ile;
this polymorphism was excluded from further analysis by
the low frequency of heterozygous genotypes. The fre-
quencies of polymorphisms Gln27Glu and Arg16Gly
were in accordance with Hardy Weinberg equilibrium.
The difference in the distribution of the genotypes of pol-
ymorphism Gln27Glu was statistically significant relative
to ethnicity (χ2 = 9.965; p = 0.04); the difference was not
significant for genotypes of polymorphism Arg16Gly. The
distribution of genotypes of polymorphism Arg16Gly was
statistically significant relative to body mass index ana-
lyzed as an ordinal variable (χ2 = 9.797; p = 0.04, being
genotype Arg/Arg associated with a higher frequency of a
BMI above 25), but not when it was analyzed as a contin-
uous variable (BMI mean values (SD): Arg/Arg 26.32
(5.75), Arg/Gly 25.61 (5.44), Gly/Gly 25.14 (5.13); p =
0.34); no significant difference was observed for geno-
types of polymorphism Gln27Glu.
The difference in the distribution of genotypes of both
polymorphisms Arg16Gly and Gln27Glu was not statisti-
cally significant relative to diabetes mellitus, history of
arterial hypertension, smoking, cardiac rhythm, etiology
of heart failure, and mortality. Detailed information
regarding frequency, means and standard deviations for
demographic and biochemical variables per genotypic
groups are available as Supplementary information (see
Additional file 1).
Outcome
188 (38%) of 501 patients died during the mean follow-
up of 12.6 (standard deviation 10.3; median 11) months.
The probability of survival revealed a statistically signifi-
cant differencerelative to the etiologies of heart failure
(log-rank, p = 0.02) (individuals with the diagnosis of Idi-
opathic Dilated Cardiomyopathy having the worst prog-
nosis). The probability of survival did not reveal a
statistically significant difference relative to the 3 geno-
types of polymorphism Gln27Glu (Gln27Gln, Gln27Glu,
Glu27Glu) and relative to the three genotypes of poly-
morphism Arg16Gly (Arg16Arg, Arg16Gly, Gly16Gly).
A Cox proportional hazards model constructed for the
entire population revealed that the variables significantly
associated with prognosis were serum sodium (higher or
under 136 mEq/l), serum creatinine, and etiology of heart
failure (data not shown). These variables were used for
adjustment in models derived from the exploratory anal-
ysis.
Next, we have performed exploratory analysis through
classification trees with the aim of identifying a potential
subgroup of heart failure patients where B2 adrenergic
genotype might be of predictive value. For this we have
used in model's construction the following variables: gen-
otype for the Arg16Gly polymorphism, genotype for the
Gln27Glu polymorphism, ethnicity, age, sex, and HF eti-
ology. Interestingly, the best classification model selected
(Figure 1) incorporated information from the Gln27Glu
polymorphism. The genotypic information derived from
this marker was able to sub-classify individuals older than
65 years into a mortality high-risk group (65% chance of
dying) and an intermediate-risk group (38% chance of
dying).
We have tested the use of this information through mod-
eling time to event (death) in the entire population in a
new Cox regression model, but adding both Gln27Glu
information and the interaction term Gln27Glu*age in
the model. In this new model (using data from 471 cases
and 185 events), not only the interaction term was signif-
icantly associated with mortality, but the marginal term
for the Gln27Glu polymorphism was also associated with
Table 3: Allelic and genotypic frequencies of polymorphisms 
Gln27Glu, Arg16Gly, and Thr164Ile in the study sample of 
patients with heart failure
Allelic frequencies Patients
N (%)
Arg 421 (42)
Gly 583 (58)
Gln 702 (71)
Glu 290 (29)
Thr 983 (99)
Ile 9 (1)
Genotypic frequencies N (%) N (%) N (%)
Arg16Gly Arg16Arg
98 (20)
Arg16Gly
225 (45)
Gly16Gly
179 (35)
Gln27Glu Gln27Gln
253 (51)
Gln27Glu
196 (39)
Glu27Glu
47 (9)
Thr164Ile Thr164Thr
487 (98)
Thr164Ile
9 (2)
Ile164Ile
- (-)
Haplotypic frequencies (%)
Arg16/Gln27 40
Arg16/Glu27 2
Gly16/Gln27 30
Gly16/Glu27 28
* samples lost due to technical difficultiesBMC Cardiovascular Disorders 2009, 9:50 http://www.biomedcentral.com/1471-2261/9/50
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heart failure mortality in our population. Both terms
remained significantly associated with mortality even
after adjustment for age, serum sodium, serum creatinine,
ethnicity, baseline beta-blocker use, and heart failure eti-
ology (Table 2). In fact, while a significant difference in
relation to overall mortality was not observed for
Gln27Glu genotypes in heart failure individuals younger
than 65 years of age, a clear difference was observed when
only individuals older than 65 years were analyzed (a sub-
group comprising 30% of the studied sample) (Figure 2).
In addition, a tendency towards increased mortality of
Glu allele carriers was present in older individuals with
both systolic and diastolic types of heart failure included
in our cohort.
Taking into account the linkage disequilibrium between
Arg16Gly and Gln27Glu (in our population of 93), our
data point to an effect derived specifically form the Glu27
allele. First, allele analysis in older individuals were only
able to disclose a significant association for the Glu27
allele (p = 0,002 for mortality), but not for the Arg16 or
Gly16 allele (p = 0,33). Second, haplotype analysis
showed a higher frequency of the Gly16/Glu27 haplotype
in individuals who died (p = 0,001), but a lower fre-
Classification Tree derived from exploratory analysis Figure 1
Classification Tree derived from exploratory analysis.BMC Cardiovascular Disorders 2009, 9:50 http://www.biomedcentral.com/1471-2261/9/50
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Kaplan-Meir survival curves for the Gln27Glu polymorphism per age group Figure 2
Kaplan-Meir survival curves for the Gln27Glu polymorphism per age group. Gray lines: GlnGln genotype; black 
lines: GlnGlu + GluGlu genotypes.
A.
B.BMC Cardiovascular Disorders 2009, 9:50 http://www.biomedcentral.com/1471-2261/9/50
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quency of the Gly16/Gln27 in individuals that died (p =
0,03). No difference was observed for the Arg16/Gln27
between patients who died and patients that did not, and
the Arg16/Glu27 was, as expected, very rare in these indi-
viduals. These data suggest that, in fact, the effect was only
present for the Gln27Glu polymorphism, and not derived
indirectly from the strong LD pattern with the Arg16Gly
polymorphism.
Discussion
The different genotypes of polymorphisms Gln27Glu and
Arg16Gly were present in the study sample in a distribu-
tion in accordance with previous reports including a Bra-
zilian population sample [9]. Most genotypes of
polymorphism Thr164Ile were homozygous for
Thr164Thr; no patient homozygous for Ile164Ile was
identified. Thr164Ile was identified only in 9 patients
(2%), a lower frequency than observed in a previous
experiment [3]. The number was considered small to the
point of hindering appropriate statistical analysis and fur-
ther analysis of this polymorphism relative to survival rate
was not performed.
We observed a significant difference in the distribution of
the polymorphism Arg16Gly relative to body mass index
in this study sample of patients with heart failure. In a pre-
vious study of a general population sample, Arg16Gly
polymorphism interacted significantly with body mass
index to determine systolic blood pressure. Further, the
presence of Arg16 allele was associated with 1.49-fold
increase in the risk of obesity in multiple logistic regres-
sion model [9]. Thus, the relationship between the pres-
ence of Arg16 and body mass index may be operative also
in patients with heart failure. Nevertheless, we have not
observed a significant effect of this genetic marker in rela-
tion to mortality.
We were not able to demonstrate a significant association
between survival rate for the overall sample and the differ-
ent genotypes, alleles or haplotypes of polymorphisms
Gln27Glu and Arg16Gly in this study sample at the signif-
icance level of p < 0.05. The significant variables associ-
ated with mortality - low body mass index [10], etiology
of heart failure [11], serum sodium [12], serum creatinine
[13] are known from previous experiences. Interestingly,
we have observed a potential interaction between age and
Gln27Glu polymorphism in modulating mortality inci-
dence of the studied patients. In this scenario, the
Gln27Glu polymorphism is predictive of a higher mortal-
ity only in individuals older than 65 years of age. Allele
and haplotype analysis suggest that the main predictor of
this effect was the Gln27Glu polymorphism and not, indi-
rectly, the Arg16Gly polymorphism.
Similar to Ligget et al. [2] and to De Groote et al. [14] we
did not find a significant association between the
Arg16Gly and Gln27Glu polymorphism and survival
when analyzing the entire population. Different from the
described by De Groote et al., however, we observed a ten-
dency of a lower survival rate in the Gly16Glu27 haplo-
type and not the Gly16Gln27 haplotype [14].
Nevertheless, we are not the first group to describe this
particular association. Forleo et al. [15] also described a
significantly higher risk for death from heart failure
(among other end-points) associated with the Glu27
allele in homozygosis in a similar population than ours,
patients with dilated cardiomyopathy. Others, however,
have observed exactly the opposite association [16,17]. In
particular, Heckbert et al, studying a large sample of eld-
erly individuals without heart failure observed the Glu27
allele to be associated with a lower risk of incident coro-
nary events [18]. Since the Gln27Glu polymorphism may
modulate the response to beta-blocker treatment in
humans [19], different frequency of beta-blocker use in
these different populations and different studied clinical
scenarios may explain, at least in part, such discordant
findings.
Our study has limitations. Demographic and clinical char-
acteristics of the patients in this study sample may also
have been operative for our findings. Specifically, in
patients with severe disease in an advanced stage of its nat-
ural history, other variables denoting the clinical condi-
tion may be more significant for the evaluation of
prognosis than a specific genetic substrate. Different etiol-
ogies of heart failure in this study sample may also limit
the observation. For several baseline predictors we were
unable to acquire complete information and we did not
have access to follow-up information on medical therapy
that could not only modulate overall survival, but also the
effect of a particular genotype. Finally, the duration of fol-
low-up was only mid-term.
Conclusion
The distribution of genotypes of polymorphism Arg16Gly
was statistically significant relative to body mass index.
We were not able to demonstrate a prognostic influence of
polymorphisms Gln27Glu and Arg16Gly of beta-2 recep-
tor gene, as individual alleles or as haplotypes, for the
entire spectrum of patients with heart failure. Rather,
there appears to be a specific modulating effect of the
Gln27Glu polymorphism in individuals older than 65
years and heart failure. Further studies should address the
specific role of the Glu27 allele in heart failure deteriora-
tion, especially in older individuals.
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